Kancera AB (publ) (KAN.ST)
SEK 1.29
(24.85%)
SEK 1.29
(24.85%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.96 Million SEK | -600.0% |
| 2022 | 393 Thousand SEK | -71.6% |
| 2021 | 1.38 Million SEK | 2096.83% |
| 2020 | 63 Thousand SEK | -97.98% |
| 2019 | 3.12 Million SEK | 990.91% |
| 2018 | 286 Thousand SEK | 633.33% |
| 2017 | 39 Thousand SEK | -84.08% |
| 2016 | 245 Thousand SEK | 17.79% |
| 2015 | 208 Thousand SEK | 26.83% |
| 2014 | 164 Thousand SEK | -87.22% |
| 2013 | 1.28 Million SEK | 32.0% |
| 2012 | 972 Thousand SEK | -33.33% |
| 2011 | 1.45 Million SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2023 Q3 | -67 Thousand SEK | -118.31% |
| 2023 Q4 | 443 Thousand SEK | 761.19% |
| 2023 FY | -1.96 Million SEK | -600.0% |
| 2023 Q2 | 366 Thousand SEK | 695.65% |
| 2023 Q1 | 46 Thousand SEK | 173.02% |
| 2022 Q4 | -63 Thousand SEK | -148.46% |
| 2022 Q3 | 130 Thousand SEK | -5.11% |
| 2022 Q1 | 189 Thousand SEK | -82.61% |
| 2022 Q2 | 137 Thousand SEK | -27.51% |
| 2022 FY | 393 Thousand SEK | -71.6% |
| 2021 Q4 | 1.08 Million SEK | 233.44% |
| 2021 FY | 1.38 Million SEK | 2096.83% |
| 2021 Q1 | 475 Thousand SEK | 110.17% |
| 2021 Q2 | -90 Thousand SEK | -118.95% |
| 2021 Q3 | 326 Thousand SEK | 462.22% |
| 2020 Q2 | 3.57 Million SEK | 25407.14% |
| 2020 FY | 63 Thousand SEK | -97.98% |
| 2020 Q3 | 49 Thousand SEK | -98.63% |
| 2020 Q4 | -4.67 Million SEK | -9632.65% |
| 2020 Q1 | 14 Thousand SEK | 111.02% |
| 2019 Q1 | 3.11 Million SEK | 991.58% |
| 2019 FY | 3.12 Million SEK | 990.91% |
| 2019 Q4 | -127 Thousand SEK | -156.7% |
| 2019 Q3 | 224 Thousand SEK | -60.84% |
| 2019 Q2 | 572 Thousand SEK | -81.61% |
| 2018 Q4 | 285 Thousand SEK | 1195.45% |
| 2018 FY | 286 Thousand SEK | 633.33% |
| 2018 Q3 | 22 Thousand SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2017 FY | 39 Thousand SEK | -84.08% |
| 2017 Q2 | 57 Thousand SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q4 | -18 Thousand SEK | 0.0% |
| 2016 Q3 | 30 Thousand SEK | 400.0% |
| 2016 Q1 | 95 Thousand SEK | 1800.0% |
| 2016 FY | 245 Thousand SEK | 17.79% |
| 2016 Q4 | 114 Thousand SEK | 280.0% |
| 2016 Q2 | 6000.00 SEK | -93.68% |
| 2015 Q4 | 5000.00 SEK | -96.35% |
| 2015 FY | 208 Thousand SEK | 26.83% |
| 2015 Q1 | 3000.00 SEK | -83.33% |
| 2015 Q3 | 137 Thousand SEK | 117.46% |
| 2015 Q2 | 63 Thousand SEK | 2000.0% |
| 2014 Q2 | 54 Thousand SEK | -49.06% |
| 2014 Q4 | 18 Thousand SEK | 228.57% |
| 2014 FY | 164 Thousand SEK | -87.22% |
| 2014 Q3 | -14 Thousand SEK | -125.93% |
| 2014 Q1 | 106 Thousand SEK | -90.56% |
| 2013 Q4 | 1.12 Million SEK | 1236.9% |
| 2013 Q3 | 84 Thousand SEK | 10.53% |
| 2013 Q2 | 76 Thousand SEK | 0.0% |
| 2013 FY | 1.28 Million SEK | 32.0% |
| 2013 Q1 | - SEK | -100.0% |
| 2012 Q3 | 450 Thousand SEK | 2150.0% |
| 2012 Q1 | 197 Thousand SEK | -48.29% |
| 2012 Q4 | 305 Thousand SEK | -32.22% |
| 2012 FY | 972 Thousand SEK | -33.33% |
| 2012 Q2 | 20 Thousand SEK | -89.85% |
| 2011 Q1 | -533 Thousand SEK | 0.0% |
| 2011 Q2 | 1.28 Million SEK | 340.9% |
| 2011 Q3 | 446 Thousand SEK | -65.26% |
| 2011 Q4 | 381 Thousand SEK | -14.57% |
| 2011 FY | 1.45 Million SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.174% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.124% |
| Mendus AB (publ) | 28.48 Million SEK | 106.898% |
| Lipum AB (publ) | 53 Thousand SEK | 3807.547% |
| NextCell Pharma AB | -43.74 Million SEK | 95.508% |
| Simris Alg AB (publ) | 2 Million SEK | 197.907% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 117.516% |
| Active Biotech AB (publ) | -1.67 Million SEK | -17.313% |
| Amniotics AB (publ) | -1.93 Million SEK | -1.813% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -364.539% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.567% |
| Cantargia AB (publ) | -3.45 Million SEK | 43.06% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 218.516% |
| CombiGene AB (publ) | -21.29 Million SEK | 90.771% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 45.112% |
| Genovis AB (publ.) | 54 Million SEK | 103.639% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -13000.0% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 94.29% |
| Intervacc AB (publ) | -13.79 Million SEK | 85.755% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 170.004% |
| LIDDS AB (publ) | -12.92 Million SEK | 84.793% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 61.599% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 119.723% |
| OncoZenge AB (publ) | 3000.00 SEK | 65600.0% |
| Saniona AB (publ) | 11.78 Million SEK | 116.679% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 42.561% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 105.553% |
| Xintela AB (publ) | 78 Thousand SEK | 2619.231% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 78.627% |
| Ziccum AB (publ) | -23.28 Million SEK | 91.561% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 98.777% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 104.702% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 190.511% |
| Corline Biomedical AB | 28.38 Million SEK | 106.924% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 98.399% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 107.326% |
| Aptahem AB (publ) | 2.63 Million SEK | 174.696% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 2651.948% |
| Fluicell AB (publ) | 1.73 Million SEK | 213.061% |
| Biovica International AB (publ) | 6.87 Million SEK | 128.574% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 91.56% |
| AcouSort AB (publ) | 8.38 Million SEK | 123.424% |
| Abliva AB (publ) | -35.66 Million SEK | 94.49% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 98.662% |
| 2cureX AB (publ) | -37.48 Million SEK | 94.758% |
| I-Tech AB | 27.56 Million SEK | 107.128% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 102.77% |
| Cyxone AB (publ) | 2.61 Million SEK | 175.259% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 157.743% |
| Biosergen AB | -456 Thousand SEK | -330.921% |
| Nanologica AB (publ) | -76 Thousand SEK | -2485.526% |
| SynAct Pharma AB | -778 Thousand SEK | -152.571% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -918.135% |
| BioInvent International AB (publ) | 71.46 Million SEK | 102.75% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | 109.887% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 105.413% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 234.311% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -87.321% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 162.719% |